Axa Investment Managers was among the participants in a $13.9m round for Alydia, which is developing a system to treat postpartum haemorrhage.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

There are occasional silver linings even for the blackest clouds. One was as the Covid-19 disease broke out this year competition for deals became a little lighter.

Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.

Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.

Tech Launch Arizona has crossed the milestone of 100 spinouts in its portfolio after achieving a new annual record in the 2019-2020 fiscal year.

Cerevel Therapeutics, co-founded by Pfizer, is set to undertake a reverse merger with Nasdaq-listed Arya II in a deal that will give Cerevel a market cap of $1.3bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU and backed by Exact Sciences and Blue Cross and Blue Shield Association, has raised $257m in series B funding.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.